Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints (CML)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01216085
First received: September 27, 2010
Last updated: April 11, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)